Zocor Offer Draws Predatory Pricing Accusations

Law360, New York (June 22, 2006, 12:00 AM EDT) -- With a generic version of cholesterol drug Zocor hitting shelves today, an offer by Merck & Co. to provide the drug for below the generic price has some accusing the pharmaceutical company of predatory pricing.

Merck offered to sell the brand-name drug to insurance providers at a lower price than Teva Pharmaceuticals, which won the rights to a 180-day period of market exclusivity for a generic version of Zocor.

The insurance provider would in turn offer the drug to patients for the co-payment fee normally charged...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.